Hims to acquire blood collection company YourBio
Hims didn’t disclose the price it’s paying for YourBio, but said it’s a cash deal expected to close in 2026.
Hims & Hers struck a deal to buy blood collection company YourBio, Hims said Wednesday.
YourBio makes a device that uses “bladeless microneedles thinner than an eyelash” to collect blood samples painlessly. The announcement comes just weeks after Hims rolled out its Labs app, which analyzes bloodwork and recommends treatments.
Hims didn’t specify exactly how YourBio’s product will be integrated or what it would pay to buy the company.
Hims acquired an at-home blood-testing facility, Trybe Labs, in February for $5.1 million. It’s being used to onboard patients in Hims’ new hormone treatment segments. Its labs product is through a partnership with Quest Diagnostics.
Hims said it expects the acquisition to close in 2026 and that it was a cash deal. According to its latest quarterly filing, the company had $345.8 million in cash and cash equivalents.
Hims raised $1 billion in May, which CEO Andrew Dudum said would help the company invest in focus areas like international expansion and artificial intelligence. It acquired a European peer, Zava, in July for $265.7 million.
